ArticleJournal, genetic engineering & biotechnology2018
Article in Journal, genetic engineering & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Immunopharmacological design of a multi-epitope vaccine targeting hepatitis C virus genotype 3a.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immunopharmacological and structural design of a polyprotein based multi epitope vaccine against Powassan virus.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The hydatid cyst fluid protein EgAgB8/1 demonstrates potent immunogenicity by eliciting robust humoral and cellular immune responses in mice.PLoS neglected tropical diseases · 2026Article
- Molecular, structural and functional characterization of flavonol synthase gene and its encoded protein in Millettia pinnata.Biotechnology letters · 2026Article
- Strategies for Monitoring Serum Protein Degradation With an Antibody Array-Based Technology.Journal of clinical laboratory analysis · 2026Article
- EP9158H: An Immunoinformatics-Designed mRNA Vaccine Encoding Multi-Epitope Antigens and Dual TLR Agonists for Tuberculosis Prevention.Bioengineering (Basel, Switzerland) · 2025Article
- Computational development of multi-epitope vaccine to induce adaptive immunity against multi-drug resistant Prevotella intermedia.BMC infectious diseases · 2025Article
- BioengineeringMicroorganisms · 2025Article
- In silico and structural analysis of Bacillus licheniformis FAO.CP7 pullulanase isolated from cocoa (Theobroma cacao L.) pod waste.BMC microbiology · 2025Article
- Discovery andACS omega · 2025Article
- Isobaric Tagging and Data Independent Acquisition as Complementary Strategies for Proteome Profiling on an Orbitrap Astral Mass Spectrometer.Journal of proteome research · 2025Article
- Enhancing Proteome Coverage by Using Strong Anion-Exchange in Tandem with Basic-pH Reversed-Phase Chromatography for Sample Multiplexing-Based Proteomics.Journal of proteome research · 2024Article
- Exploring the Structural Insights of ThermostableACS omega · 2024Article
- Article
- Plasmodium vivax serological exposure markers: PvMSP1-42-induced humoral and memory B-cell response generates long-lived antibodies.PLoS pathogens · 2024Article
- Spin column-based peptide fractionation alternatives for streamlined tandem mass tag (SL-TMT) sample processing.Journal of proteomics · 2023Article
- Thermoactive metallo-keratinase fromHeliyon · 2023Article
- Isolation of Saccharibacillus WB17 strain from wheat bran phyllosphere and genomic insight into the cellulolytic and hemicellulolytic complex of the Saccharibacillus genus.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Novel Feather Degrading Keratinases fromMicroorganisms · 2022Article
- Comparative molecular docking and molecular-dynamic simulation of wild-type- and mutant carboxylesterase with BTA-hydrolase for enhanced binding to plastic.Engineering in life sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xylans are the second most abundant form of hemicelluloses and are the second most abundant polysaccharide in nature after cellulose. To degrade xylan, microbes produce mainly xylanase enzyme. Wide range of microorganisms like fungi, bacteria, yeast, marine algae etc. are capable of producing xylanase. Main source of xylanase is fungi but industrial production of bacterial xylanase is low cost, easy downstream process and high production rate. To understand primary, secondary and tertiary structure of xylanase,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.